MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2026 International Congress

    Multimodal Imaging in Cervical Dystonia with Botulinum Toxin Treatment: A Pilot 5.0T MRI and 99mTc-MIBI SPECT/CT Study

    J. Li, L. Wang, X. Song, L. He, Y. Wang, J. Li, Y. Liu, S. Li, K. Li (Beijing, China)

    Objective: To comprehensively investigate structural, vascular, and metabolic alterations in cervical dystonia (CD) patients using ultra-high-field 5.0T magnetic resonance imaging (MRI) and 99mTc-MIBI SPECT/CT. Background:…
  • 2026 International Congress

    Presence of Common Psychiatric Diagnoses Did Not Impact the Efficacy or Safety of Ecopipam in Individuals With Tourette Syndrome

    J. Mcguire, J. Flatt, G. Karkanias, F. Munschauer, T. Cunniff, S. Wanaski, E. Greenberg (Baltimore, USA)

    Objective: To evaluate ecopipam efficacy/safety in individuals with Tourette syndrome (TS) with or without common psychiatric comorbidities. Background: Co-occurring psychiatric conditions are frequently observed with…
  • 2026 International Congress

    Characteristics of participants of the Australian National Disability Insurance Scheme with Parkinson’s disease

    J. Mcginley, K. Bower, V. Mcconvey, M. Callisaya, A. Khan, M. Ho, D. Shen, S. Fernando, M. Klaic, S. Soh (Parkville, Australia)

    Objective: To evaluate the demographic characteristics, goals and funding of participants with Parkinson’s disease (PD) in the Australian National Disability Insurance Scheme (NDIS). Background: The…
  • 2026 International Congress

    Functional Improvement Following Early GPi-DBS for Moderate-Stage Atypical KMT2B Dystonia: A Case Report in a 13-Year-Old Girl

    Z. Sclavont, V. Leclercq, C. Vilain, S. Schuind, F. Supiot, N. Deconinck, P. van Gyseghem (Brussels, Belgium)

    Objective: To report clinical trajectory and functional improvement of a child with atypical KMT2B-related dystonia following bilateral GPi-DBS performed at a moderate disease stage. Background:…
  • 2026 International Congress

    Relationships of serum & CSF Transcobalamin Receptor Antibodies to CSF vitamin B12, holotranscobalamin and clinical progression in Parkinson’s disease

    C. Christine, J. Pluvinage, P. Auinger, L. Tat, E. Forti, R. Green, M. Wilson (San Francisco, USA)

    Objective: To measure serum & CSF transcobalamin receptor antibodies (CD320ab) in patients with early Parkinson’s disease (PD) and to assess their relationships to CSF vitamin…
  • 2026 International Congress

    Nutritional status, clinical Features and lifestyle of Twins Discordant for Parkinson’s Disease

    M. Barichella, A. Natale, E. Cereda, E. Contaldi, L. Magistrelli, C. Bolliri, M. Macchione, F. Invernizzi, D. Calandrella, I. Isaias, G. Pezzoli (Milano, Italy)

    Objective: To characterize nutritional status (body weight, body mass index [BMI]), dietary habits, and lifestyle factors (smoking) of twins discordant for Parkinson’s disease (PD). Background:…
  • 2026 International Congress

    Development of a Nationwide Parkinson’s Disease Cohort in Korea: Toward an Ethnicity-Specific Precision Medicine Platform

    JS. Kim, DW. Ryu, Y. Oh, S. Ha, SJ. Kim, ES. Oh, YJ. Kim, PH. Lee, SJ. Chung, SB. Koh, DY. Kwon, JW. Cho, JS. Baik, HI. Ma, TB. Ahn, HW. Lee, JK. Park, M. Kwon, YH. Koh, SW. Yoo (Seoul, Republic of Korea)

    Objective: To establish and longitudinally expand a nationwide Parkinson’s disease (PD) cohort in Korea (K-PD cohort) and develop an ethnicity-specific precision medicine platform integrating clinical,…
  • 2026 International Congress

    Anti Tremorgenic Properties Of Eslicarbazepine Acetate in The Harmaline Induced Tremor Mouse Model

    A. Coelho, A. Evrard, C. Roucard, T. Fonseca, V. Di Foggia, P. Soares-da-Silva, J. Holenz, N. Pires (São Mamede do Coronado, Portugal)

    Objective: This study evaluated potential anti-tremor properties of eslicarbazepine acetate (ESL), an antiseizure medication approved for treatment of focal-onset epilepsy, in the harmaline-induced tremor mouse…
  • 2026 International Congress

    Longitudinal Decline of Alanine Aminotransferase Activity in Parkinson’s Disease and Its Association with Disease Duration

    G. Maayan Eshed, M. Shemesh, N. Omer, R. Alcalay, M. Gana-Weisz, O. Goldstein, A. Mirelman, A. Thaler (San Francisco, USA)

    Objective: To characterize longitudinal trajectories of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activity and the neutrophil-to-lymphocyte ratio (NLR) in Parkinson’s disease (PD) and healthy…
  • 2026 International Congress

    Categorization and Characterization of Cognitive Phenotypes in Parkinson’s Disease Using Machine Learning.

    H. Trujillo-Guerra, R. Trejo-Ayala, P. Téllez-Hernández, J. Esquivel-Del Río, B. Chávez-Luévanos, I. Estrada-Bellmann, X. Ortiz-Jiménez (Monterrey, Mexico)

    Objective: To categorize cognitive phenotypes in patients with Parkinson's Disease (PD) using an unsupervised algorithm and validate their clinical, psychiatric, and motor differences. Background: Four…
  • « Previous Page
  • 1
  • …
  • 27
  • 28
  • 29
  • 30
  • 31
  • …
  • 208
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley